Introduction {#s1}
============

Model, rod-shaped organisms such as *Escherichia coli* and *Bacillus subtilis* elongate across a broad swath of the cell ([@bib17]; [@bib16]). Mycobacterial cells, by contrast, extend from narrower polar regions ([@bib1]; [@bib57]; [@bib44]; [@bib66]; [@bib31]; [@bib63]; [@bib27]). Circumscription of growth to discrete zones poses spatial challenges to the bacterial cell. For example, if polar growth and division are the only sites of cell wall synthesis in mycobacteria, the entire lateral surface of the cell must be inert ([@bib1]; [@bib11]; [@bib34]; [@bib71]). Such an expanse of non-renewable surface could leave the cell vulnerable to environmental or immune insults.

Because cell wall peptidoglycan synthesis is critical for bacterial replication, it is often used to localize the sites of growth and division. Intriguingly, [d]{.smallcaps}-amino acid probes, which in other species have been shown to incorporate into peptidoglycan ([@bib17]; [@bib34]; [@bib61]), label both the poles and sidewall of mycobacteria ([@bib44]; [@bib61]; [@bib9]; [@bib8]; [@bib60]; [@bib55]). The localization of these molecules is supported by the detection of peptidoglycan synthetic enzymes at the mycobacterial cell tips and periphery ([@bib44]; [@bib27]; [@bib26]; [@bib29]; [@bib49]). However, both intracellular and extracellular incorporation pathways have been characterized or hypothesized for [d]{.smallcaps}-amino acid probes, complicating the interpretation of labeling patterns ([@bib62]). Intracellular uptake implies that the probe enters the biosynthetic pathway at an early stage, and therefore marks nascent cell wall. Extracellular incorporation, on the other hand, suggests that the probe enters the pathway at a later stage and/or is part of enzymatic remodeling of the macromolecule in question. The extent to which peptidoglycan synthesis and remodeling are linked is not clear ([@bib11]; [@bib18]; [@bib23]) and may vary with species and external milieu. In *Mycobacterium tuberculosis*, for example, there is indirect but abundant data that suggest that there is a substantial cell envelope remodeling during infection when growth and peptidoglycan synthesis are presumed to be slow or nonexistent ([@bib31]).

An intracellular metabolic tagging method for the cell wall would be an ideal tool for determining whether tip-extending mycobacteria can synthesize peptidoglycan along their lateral surfaces. At least two pieces of evidence suggest that [d]{.smallcaps}-alanine-[d]{.smallcaps}-alanine dipeptide probes are incorporated into peptidoglycan via the cytoplasmic MurF ligase ([@bib39]; [@bib58]). First, derivatives of [d]{.smallcaps}-alanine-[d]{.smallcaps}-alanine rescue the growth of *Chlamydia trachomatis* treated with [d]{.smallcaps}-cycloserine, an antibiotic that inhibits peptidoglycan synthesis by inhibiting the production and self-ligation of [d]{.smallcaps}-alanine in the cytoplasm ([@bib39]). Second, *B. subtilis* cells stripped of mature peptidoglycan by lysozyme treatment retain a small amount of dipeptide-derived fluorescence ([@bib58]). While these data are suggestive, formal demonstration of intracellular incorporation requires direct evidence that the probe labels peptidoglycan precursors. More broadly, better characterization of the metabolic fate of probes would increase the precision of conclusions that can be drawn from labeling experiments ([@bib10]; [@bib53]).

Here, we sought to determine how [d]{.smallcaps}-amino acid probes incorporate into the mycobacterial cell wall. Monopeptide [d]{.smallcaps}-amino acid probes chiefly reported peptidoglycan remodeling by [l]{.smallcaps},[d]{.smallcaps}-transpeptidases while dipeptides marked lipid-linked peptidoglycan precursors. All the probes tested labeled the poles and sidewall of mycobacteria, indicating that cell wall metabolism in these regions comprises both synthetic and remodeling reactions. While peptidoglycan assembly along the mycobacterial periphery did not support obvious surface expansion, it was greatly enhanced by cell wall damage. Such activity may allow editing of a complex, essential structure at timescales faster than those permitted by polar growth.

Results {#s2}
=======

Metabolic labeling of mycobacterial envelope comprises asymmetric polar gradients {#s2-1}
---------------------------------------------------------------------------------

Mycobacteria have been shown to expand from their poles ([@bib1]; [@bib57]; [@bib44]; [@bib66]; [@bib31]; [@bib63]; [@bib27]) but published micrographs suggest that [d]{.smallcaps}-amino acid probes may label both the poles and sidewall of these organisms ([@bib44]; [@bib61]; [@bib9]; [@bib8]; [@bib60]; [@bib55]). Metabolic labeling can be achieved by a one-step process, in which the fluorophore is directly appended to the probe, or a two-step process in which a small chemical tag on the [d]{.smallcaps}-amino acid is detected by subsequent reaction with a fluorescent reactive partner (\[[@bib62]\], [Figure 1A](#fig1){ref-type="fig"}). We first reexamined the localization of various [d]{.smallcaps}-amino acid probes reported in the literature, including RADA ([@bib34]), which is directly conjugated to 5-carboxytetramethylrhodamine, and the two-step alkyne-[d]{.smallcaps}-alanine \[alkDA or EDA, ([@bib34]; [@bib61])\], and alkyne-[d]{.smallcaps}-alanine-[d]{.smallcaps}-alanine (alkDADA or EDA-DA, ([@bib39]); we use the metabolic labeling nomenclature originally adopted in \[[@bib40]\]) which we detected by copper-catalyzed azide-alkyne cycloaddition (CuAAC) after fixation ([Figure 1B and C](#fig1){ref-type="fig"}). After *M. smegmatis* cells were incubated for \~10% generation in probe, high-resolution and quantitative microscopy revealed that they had asymmetric, bidirectional gradients of fluorescence that emanated from the poles and continued along the sidewall ([Figure 2A](#fig2){ref-type="fig"}). Polar gradients of dipeptide labeling were also apparent in live cells when we detected azido-[d]{.smallcaps}-alanine-[d]{.smallcaps}-alanine (azDADA or ADA-DA, \[[@bib39]\]) incorporation by either CuAAC (using low copper, bio-friendly reaction conditions (\[[@bib69]\], [Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}) or by copper-free, strain-promoted azide-alkyne cycloaddition (SPAAC, [Figure 2---figure supplement 1B](#fig2s1){ref-type="fig"}).

![Cell envelope metabolic labeling in mycobacteria.\
(**A**) Schematic of one- and two-step metabolic labeling. Top, a cell envelope precursor or 'probe' bearing a reactive group is incorporated into the envelope by the endogenous enzymatic machinery of the cell. The presence of the probe is then revealed by a chemical reaction with a label that bears a complementary reactive group. Bottom, in some cases the probe can be pre-labeled, bypassing the chemical ligation step and embedding the detection moiety directly into the macromolecule. Yellow star, fluorophore. See ([@bib62]) for more details. (**B**) Probes used in this work to mark the mycobacterial envelope. See text for details. Colored and black chemical structures denote probes used in one- and two-step labeling, respectively. C, X and Y reactive partners used in this work for two-step labeling as shown in A. CuAAC, copper-catalyzed azide-alkyne cycloaddition; SPAAC, strain-promoted azide-alkyne cycloaddition.](elife-37243-fig1){#fig1}

![Asymmetric polar gradients of cell envelope metabolic labeling in mycobacteria.\
(**A**) *M. smegmatis* was incubated for 15 min (\~10% generation) in the indicated probe, then washed and fixed. Alkynyl probes were detected by CuAAC with azido-CR110 and cells were imaged by structured illumination microscopy. MM, mycomembrane; AG, arabinogalactan; PG, peptidoglycan; PM, plasma membrane. (**B**) *M. smegmatis* dual labeled with RADA and alkDADA, left, or RADA and OalkTMM, right, and imaged by conventional fluorescence microscopy. (**C**) *M. smegmatis* was labeled as in B and cellular fluorescence was quantitated for cells without (top; 77 \< n \< 85) or with (bottom; 9 \< n \< 51) visible septa for RADA, OalkTMM and alkDADA. Signal was normalized to cell length and to total fluorescence intensity. Cells were oriented such that the brighter pole is on the right hand side of the graph. (**D**) *M. smegmatis* (Msm; light blue) or *M. tuberculosis* (Mtb; dark blue) was labeled with HADA for 15 min or 2 hr (\~10% generation), respectively, then washed and fixed. Fluorescence was quantitated as in C for cells without (top; 118 \< n \< 332) and with (bottom; 55 \< n \< 85) visible septa. We defined the dim pole (dp) as the sum of the fluorescence intensity over the first 15% of the cell; the sidewall (sw) as the sum of the middle 70%; and the bright pole (bp) as the sum over the final 15% of the cell. Fluor distrib, average fluorescence distribution. AU, arbitrary units. Error bars, ±standard deviation. Statistical significance between *M. smegmatis* (five biological replicates) and *M. tuberculosis* (three biological replicates) was assessed for the dim pole, sidewall and bright pole by two-tailed Student's t test. \*p\<0.05; \*\*p\<0.005.\
10.7554/eLife.37243.008Figure 2---source data 1.Conventional fluorescence and structured illumination microscopy images of mycobacteria labeled with peptidoglycan and trehalose monomyocolate probes.](elife-37243-fig2){#fig2}

The mycobacterial cell envelope is comprised of covalently bound peptidoglycan, arabinogalactan and mycolic acids, as well as intercalated glycolipids and a thick capsule (\[[@bib50]\], [Figure 1B](#fig1){ref-type="fig"}). Assembly of the envelope layers has long been presumed to be spatially coincident. This is largely based on biochemical data suggesting that ligation of arabinogalactan to peptidoglycan occurs concurrently with crosslinking of the latter by transpeptidases ([@bib24]). We and others have found that cytoplasmic enzymes that mediate arabinogalactan and mycomembrane synthesis are enriched at the poles but also present along the periphery of the cell ([@bib44]; [@bib25]; [@bib12]), as is metabolic labeling by OalkTMM and NalkTMM (\[[@bib3]; [@bib65]; [@bib21]\], [Figure 2A](#fig2){ref-type="fig"}). OalkTMM and NalkTMM are trehalose monomycolate derivatives that predominantly mark covalent mycolates and trehalose dimycolate, respectively, in the mycomembrane ([Figure 1B](#fig1){ref-type="fig"}, \[[@bib21]\]). The azido and alkynyl groups on the different probes are not orthogonal to each other ([Figure 1C](#fig1){ref-type="fig"}) so we opted to compare peptidoglycan and mycomembrane labeling patterns by using RADA as a fiducial marker. The cell pole with brighter RADA fluorescence also had more alkDADA or OalkTMM labeling ([Figure 2B](#fig2){ref-type="fig"}), suggesting that the polar orientation of peptidoglycan and mycomembrane metabolism is coincident. We then compared the fluorescence intensity profiles of cells that had been individually labeled with the probes, and found similar, average distributions of RADA, alkDADA and OalkTMM at the poles and peripheries of the cells ([Figure 2C](#fig2){ref-type="fig"}).

We next sought to address whether the cell envelope of the related *M. tuberculosis* is also labeled in polar gradients. We previously showed that alkDA incorporates into the cell surface of the organism ([@bib61]) but were unable to stain the entire population of bacteria. To investigate the origin of labeling heterogeneity, we first tested whether the structure of fluorophore ([Figure 1B](#fig1){ref-type="fig"}) influenced probe incorporation by incubating *M. tuberculosis* in HADA, NADA or RADA and assessing population fluorescence by flow cytometry. HADA and NADA incubation yielded well-defined fluorescent populations ([Figure 2---figure supplement 2A](#fig2s2){ref-type="fig"}). RADA also labeled the entire *M. tuberculosis* population, albeit with greater cell-to-cell variability in fluorescence intensity. Given that *M. tuberculosis* incorporates fluorescent probes HADA and NADA relatively evenly across the population, we hypothesized that the apparent heterogeneity that we previously observed for alkDA labeling ([@bib61]) was the result of an inefficient CuAAC ligation. We obtained very modest improvements by changing the reaction conditions, more specifically, by swapping the BTTP ligand ([@bib69]; [@bib6]) for the TBTA ligand, altering the ratio of ligand: Cu(I) and increasing the azide label concentration. We also switched our detection moiety to an azide appended to hydroxycoumarin, the same small, uncharged fluorophore as the one-step HADA probe ([Figure 1B](#fig1){ref-type="fig"}). Under our optimized conditions we detected azido-coumarin fluorescence from \~5 to 10% of cells that had been incubated in alkDA, alkDADA or OalkTMM ([Figure 2---figure supplement 2B and C](#fig2s2){ref-type="fig"}).

Although unable to achieve homogenous *M. tuberculosis* labeling with two-step envelope probes, we decided to test whether the sites of envelope labeling in the limited fluorescent subpopulation resemble those of *M. smegmatis*. HADA, alkDADA and OalkTMM tagging all produced cells that had a mixture of sidewall and polar fluorescence ([Figure 2---figure supplement 2C](#fig2s2){ref-type="fig"}) but exhibited a higher degree of cell-to-cell variability compared to *M. smegmatis*. Quantitation of HADA fluorescence showed that peptidoglycan metabolism comprised asymmetric polar gradients when averaged across the population ([Figure 2D](#fig2){ref-type="fig"}). We next asked whether there was a cell-wide difference in labeling distribution in *M. tuberculosis* compared to *M. smegmatis*. We arbitrarily defined the dimmer polar region as the first 15% of the cell length, the sidewall as the middle 70%, and the brighter polar region as the final 15%. As HADA labeled a large proportion of *M. tuberculosis* ([Figure 2---figure supplement 2A](#fig2s2){ref-type="fig"}) and was more resistant to photobleaching than NADA, we compared these ratios for HADA in septating and non-septating *M. smegmatis* and *M. tuberculosis* labeled for \~10% generation time ([Figure 2D](#fig2){ref-type="fig"}; under our growth conditions, *M. smegmatis* and *M. tuberculosis* generation times are 2.5--3 hr and 18--20 hr, respectively). Approximately 70--75% of HADA labeling in *M. tuberculosis* localized to the sidewall compared to 63--64% for *M. smegmatis* ([Figure 2D](#fig2){ref-type="fig"}). Thus, a greater proportion of peptidoglycan metabolism in *M. tuberculosis* likely occurs along the cell periphery than in *M. smegmatis*, although we cannot rule out a differential contribution of cyan autofluorescence in the two species ([@bib48]).

Intracellular and extracellular pathways of [d]{.smallcaps}-amino acid probe incorporation in mycobacteria {#s2-2}
----------------------------------------------------------------------------------------------------------

As the cell periphery is not known to support surface expansion in mycobacteria ([@bib1]; [@bib57]; [@bib44]; [@bib66]; [@bib31]; [@bib63]; [@bib27]), we sought to characterize the molecular processes that underlie [d]{.smallcaps}-amino acid labeling patterns. OalkTMM and NalkTMM are inserted directly by the extracellular Antigen 85 complex into the mycomembrane ([@bib21]). However, there are three potential pathways by which [d]{.smallcaps}-amino acid probes might incorporate into mycobacterial peptidoglycan ([@bib62]; [@bib13]; [@bib46]): an intracellular, biosynthetic route and two extracellular routes, mediated by [d]{.smallcaps},[d]{.smallcaps}-transpeptidase or [l,d]{.smallcaps}-transpeptidase remodeling enzymes ([Figure 3A](#fig3){ref-type="fig"}). Peptidoglycan remodeling, particularly by the [l,d]{.smallcaps}-transpeptidases abundantly encoded in the mycobacterial genome, may not strictly correlate with synthesis of the biopolymer ([@bib11]; [@bib34]; [@bib18]; [@bib23]). Therefore, we sought to distinguish the different routes of incorporation for [d]{.smallcaps}-amino acid probes in mycobacteria.

![Multiple pathways of [d]{.smallcaps}-amino acid probe incorporation in *M. smegmatis.*\
(**A**) Schematic of the theoretical routes of [d]{.smallcaps}-amino acid (DA) and [d]{.smallcaps}-alanine [d]{.smallcaps}-alanine (DADA) probe incorporation. LDT, [l]{.smallcaps},[d]{.smallcaps}-transeptidase, DDT, [d]{.smallcaps},[d]{.smallcaps}-transpeptidase (DDTs). For more details see [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}. (**B**) Sensitivity of HADA (blue), NADA (green), RADA (red), alkDA (light grey), alkDADA (dark grey) and OalkTMM (black) to antibiotics. Imi, imipenem + clavulanate; amp, ampicillin + clavulanate; dcs, [d]{.smallcaps}-cycloserine; vanc, vancomycin. *M. smegmatis* was pretreated or not with the indicated antibiotics at 2X MIC for 30 min then incubated an additional 15 min in the presence of probe. The bacteria were then washed and fixed. The alkyne-bearing probes were detected by CuAAC with azido-CR110 and quantitated by flow cytometry. Experiment was performed three to four times in triplicate. For each biological replicate, the averaged median fluorescence intensities (MFI) of the drug-treated samples were divided by the MFI of untreated bacteria. Data are expressed as the average percentage of untreated labeling across the biological replicates. Error bars, ±standard deviation. Statistical significance compared to alkDADA was assessed by two-tailed Student's t test of percentages for biological replicates. Horizontal black stars: \*p\<0.05; \*\*p\<0.005; \*\*\*p\<0.0005; \*\*\*\*p\<0.00005. Statistical significance compared to probe-matched controls that were not treated with antibiotic was assessed by two-tailed Student's t test of log~10~ MFI data for biological replicates. Vertical dark grey stars: \*p\<0.05; \*\*p\<0.005; \*\*\*p\<0.0005; \*\*\*\*p\<0.00005. (**C**) Effect of antibiotic dose on alkDA-derived fluorescence. *M. smegmatis* was pretreated or not with drugs at the fold-MIC indicated and labeled as in B. Experiment was performed three times in triplicate. For each biological replicate, the averaged MFI of the control (no drug, no alkDA but subjected to CuAAC) was subtracted from the averaged MFI of the drug-treated sample. This was then divided by the averaged MFI of untreated control (no drug but incubated in alkDA and subjected to CuAAC) from which the control MFI had also been subtracted. Data are expressed as the average percentage of untreated labeling across the biological replicates. Error bars, ±standard deviation. (**D**) Left, combined effects of imipenem and [d]{.smallcaps}-cycloserine on alkDA-derived fluorescence. *M. smegmatis* was pretreated or not with the drugs at the fold-MIC indicated and labeled as in B. Experiment was performed twice in triplicate with similar results. One data set is shown. The percent of untreated labeling was calculated as in C and subtracted from 100 to obtain the percent inhibition. Right, Bliss interaction scores for each pair of doses in left-hand graph were calculated as (E~I~ + E~D~ E~I~E~D~)/E~I,D~ where E~I~ is the effect of imipenem at dose *i*, E~D~ is the effect of [d]{.smallcaps}-cycloserine at dose *d* and E~I,D~ is the observed effect of the drugs at dose *i* and dose *d*. Combinations that produce Bliss scores greater than, equal to, or less than one are, respectively, interpreted as antagonistic, additive, or synergistic interactions. (**E**) Dose-dependent effect of imipenem on alkDADA (grey), HADA (blue) and RADA (red) labeling. *M. smegmatis* was pretreated or not with imipenem at the fold-MIC indicated and labeled as in B. Experiment was performed three times in triplicate and one representative data set is shown. For each technical replicate, the averaged median fluorescence intensities (MFI) of the drug-treated samples were divided by the averaged MFI of untreated bacteria. Data are expressed as the average percentage of untreated labeling across the technical replicates. Error bars, ±standard deviation. (**F**) Wildtype *M. smegmatis* pre-treated or not with 2X MIC imipenem and untreated *ΔldtABE* and complement (c ldtABE) were labeled with alkDA (white), HADA (blue), NADA (green) or RADA (red) and processed as in B. Experiment was performed two to ten times in triplicate. Representative data from one of the biological replicates is shown here. Error bars, ±standard deviation.\
10.7554/eLife.37243.013Figure 3---source data 1.Flow cytometry data of mycobacteria incorporating peptidoglycan probes in different conditions.](elife-37243-fig3){#fig3}

It seemed possible that the chemical structure of the derivative ([Figure 1B](#fig1){ref-type="fig"}) and/or number of labeling steps ([Figure 1A](#fig1){ref-type="fig"}) might influence probe uptake, so we first tested the labeling sensitivity of a panel of [d]{.smallcaps}-amino acid derivatives to antibiotics that inhibit potential incorporation routes ([Figure 3A](#fig3){ref-type="fig"}). We also assessed OalkTMM and the [d]{.smallcaps}-alanine-[d]{.smallcaps}-alanine dipeptide probe, the latter of which has been proposed to tag the peptidoglycan of other species via the cytoplasmic MurF ligase \[[Figure 3A](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}, ([@bib39]; [@bib58])\]. [d]{.smallcaps}-cycloserine is a cyclic analog of [d]{.smallcaps}-alanine that inhibits the [d]{.smallcaps}-alanine racemase (Alr) and ligase (DdlA) in mycobacteria ([@bib19]). Together with the β-lactamase inhibitor clavulanate, β-lactams like ampicillin block [d,d]{.smallcaps}-transpeptidases and [d,d]{.smallcaps}-carboxypeptidases. Broader spectrum carbapenems such as imipenem additionally inhibit [l,d]{.smallcaps}-transpeptidases ([@bib33]). We also included vancomycin, an antibiotic that interferes with transpeptidation and transglycosylation by steric occlusion, to control for general defects in periplasmic peptidoglycan assembly. We empirically determined a time frame of drug treatment that did not compromise *M. smegmatis* viability ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}). Within this time frame, labeling for all single residue [d]{.smallcaps}-amino acid probes decreased significantly in response to imipenem or [d]{.smallcaps}[-]{.smallcaps}cycloserine treatment ([Figure 3B](#fig3){ref-type="fig"}). By contrast, labeling by the dipeptide probe was relatively resistant to these antibiotics. Neither vancomycin nor ampicillin had a clear effect on labeling by any of the probes, indicating that cell death, disruption of peptidoglycan polymerization, and abrogration of [d]{.smallcaps},[d]{.smallcaps}-transpeptidation do not explain the metabolic incorporation differences. OalkTMM labeling was sensitive to [d]{.smallcaps}[-]{.smallcaps}cycloserine, but not to imipenem nor ampicillin, suggesting that transfer of mycolates to arabinogalactan may require peptidoglycan precursor synthesis but not transpeptidation.

To test whether distinct mechanisms of probe incorporation were inhibited by [d]{.smallcaps}-cycloserine and imipenem, we performed a chemical epistasis experiment. We first examined the effect of different drug concentrations on alkDA incorporation ([Figure 3C](#fig3){ref-type="fig"}). Treatment with either [d]{.smallcaps}-cycloserine or imipenem, but not ampicillin, resulted in dose-dependent inhibition of the probe-derived fluorescence that plateaued at approximately half of untreated levels. We then assessed the combined effect of [d]{.smallcaps}-cycloserine and imipenem by Bliss independence ([@bib7]), a commonly used reference model for predicting drug-drug interactions based on the dose response for the individual drugs. This method is most appropriate when dual inhibition proceeds via distinct mechanisms for example activity against different molecules, enzymes or pathways ([@bib20]). The effects of [d]{.smallcaps}-cycloserine and imipenem on alkDA incorporation were the same or slightly greater than the potencies predicted by the antibiotics individually ([Figure 3D](#fig3){ref-type="fig"}). The primarily additive nature of these antibiotics in the Bliss independence model is consistent with the idea that [d]{.smallcaps}-cycloserine and imipenem block distinct pathways of alkDA incorporation, and therefore that the probe incorporates into mycobacterial peptidoglycan via both cytoplasmic and [l,d]{.smallcaps}-transpeptidase routes.

RADA and NADA labeling were more sensitive to imipenem than HADA and alkDA ([Figure 3B](#fig3){ref-type="fig"}), at multiple concentrations of drug ([Figure 3E](#fig3){ref-type="fig"}). To test whether the probes were differentially incorporated by [l,d]{.smallcaps}-transpeptidases, we knocked out three of the six enzymes encoded in the *M. smegmatis* genome. We chose to focus on LdtA, LdtB and LdtE because the *M. tuberculosis* homologs (Ldt~MT1~, Ldt~MT2~, and Ldt~MT4,~ respectively) have been shown in vitro to have both cross-linking and [d]{.smallcaps}-amino acid exchange activity and to be inhibited by imipenem ([@bib15]). RADA and NADA fluorescence decreased by \~80--85% the absence of *ldtABE,* and this effect was complemented by the expression of *ldtA* alone ([Figure 3F](#fig3){ref-type="fig"}). We observed a more moderate effect on HADA and alkDA labeling, which were decreased by \~40--60%. Collectively these data suggest that: 1. RADA and NADA probes primarily report [l,d]{.smallcaps}-transpeptidase activity, tetrapeptide substrate, or both, and 2. HADA and alkDA likely label via both cytoplasmic and [l,d]{.smallcaps}-transpeptidase routes.

Dipeptide [d]{.smallcaps}-amino acid probe incorporates into mycobacterial peptidoglycan precursors {#s2-3}
---------------------------------------------------------------------------------------------------

As RADA labeling in mycobacteria is largely indicative of [l,d]{.smallcaps}-transpeptidase activity ([Figure 3](#fig3){ref-type="fig"}) and occurs at the poles and along the sidewall ([Figure 2](#fig2){ref-type="fig"}), we surmise that peptidoglycan is remodeled at both of these locations. We wished to determine whether remodeling was coincident with biopolymer synthesis but were limited by the multiple incorporation routes of alkDA and HADA ([Figure 3](#fig3){ref-type="fig"}). Dipeptide [d]{.smallcaps}-amino acid probes have been proposed to report peptidoglycan synthesis in other species via a cytoplasmic, MurF-dependent pathway \[[Figure 3A](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}, ([@bib39]; [@bib58])\]. Consistent with this notion, and in contrast to the monopeptide probes, alkDADA labeling was relatively stable to imipenem treatment ([Figure 3B and E](#fig3){ref-type="fig"}) and inefficiently incorporated ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). Thus we were surprised to observe that overall labeling by alkDADA decreased in the absence of LdtA, LdtB, LdtE or combinations thereof ([Figure 4---figure supplement 2A](#fig4s2){ref-type="fig"}). The reduction in signal occurred primarily at the poles ([Figure 4---figure supplement 2B](#fig4s2){ref-type="fig"}) yet loss of the enzymes did not impair bacterial growth ([Figure 4---figure supplement 3](#fig4s3){ref-type="fig"}). As we do not yet understand the mechanistic basis for this observation, we sought to directly test the hypothesis that dipeptide probes incorporate into peptidoglycan precursors.

[d]{.smallcaps}-alanine is produced in mycobacteria by Alr, the [d]{.smallcaps}-alanine racemase ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). The molecule is linked to a second [d]{.smallcaps}-alanine by DdlA, the [d]{.smallcaps}-alanine ligase, and the resulting dipeptide is added to the UDP-MurNAc-tripeptide by MurF. If the alkDADA probe is able to label mycobacterial peptidoglycan via MurF, addition of the molecule to the growth medium should rescue a mutant that is unable to make [d]{.smallcaps}-alanine-[d]{.smallcaps}-alanine. We first constructed an *alr* deletion mutant in *M. smegmatis* and verified that growth is rescued by exogenous [d]{.smallcaps}-alanine but not by alkDA ([Figure 4A](#fig4){ref-type="fig"}). Although our antibiotic data suggest that alkDA is incorporated into peptidoglycan in part via a cytoplasmic pathway ([Figure 3](#fig3){ref-type="fig"}), the inability of this probe to rescue growth was not surprising given the substrate specificities of Ddl and MurF ([@bib4]) and inefficient synthesis of UDP-MurNAc-pentapeptide with [d]{.smallcaps}-amino acids other than alanine ([@bib13]). In contrast to the alkDA results, we were able to rescue *alr* with either [d]{.smallcaps}-alanine-[d]{.smallcaps}-alanine or its alkynyl derivative ([Figure 4A](#fig4){ref-type="fig"}).

![alkDADA rescues the growth of [d]{.smallcaps}-alanine racemase (Alr) and ligase (DdlA) mutants.\
alkDADA probe supports the growth of *Δalr*, A, or temperature-sensitive *ddlA*^ts^, B. Wildtype (white bars) and *Δalr* (grey bars), B, or *ddlA*^ts^ (grey bars), were grown in the presence or absence of exogenous [d]{.smallcaps}-alanine, [d]{.smallcaps}-alanine- [d]{.smallcaps}-alanine or alkynyl derivatives thereof. Error bars, ±standard deviation. Significant differences compared to *Δalr* no [d]{.smallcaps}-alanine (\#, second bar from left), A, or *ddlA*^ts^ at 42˚C no [d]{.smallcaps}-alanine-[d]{.smallcaps}-alanine (\#, fourth bar from left), B, One-way ANOVA with Dunnett's test, are shown for 3--4 biological replicates. \*\*\*p\<0.005, \*\*\*\*p\<0.0005.\
10.7554/eLife.37243.020Figure 4---source data 1.OD~600~ measurements of growth in different mycobacterial strains and conditions.](elife-37243-fig4){#fig4}

We considered the possibility that alkDADA may be digested by a [d]{.smallcaps},[d-]{.smallcaps}carboxypeptidase prior to incorporation. This would result in the release of both unlabeled [d]{.smallcaps}-alanine and alkDA, the first of which could account for *alr* growth rescue ([Figure 4A](#fig4){ref-type="fig"}). We reasoned that a more precise gauge for MurF-dependent incorporation of the intact probe would be whether it could support the replication of a strain unable to ligate [d]{.smallcaps}-alanine to itself. Therefore, we confirmed that alkDADA rescues the growth of a temperature-sensitive *ddlA* mutant ([@bib5]) at the non-permissive temperature ([Figure 4B](#fig4){ref-type="fig"}).

Our genetic data supported a MurF-dependent pathway of alkDADA incorporation into peptidoglycan. If true, the probe should be present in precursors such as lipid I and lipid II ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). To test this hypothesis, we first optimized for mycobacteria a recently reported protocol for detecting lipid-linked precursors ([@bib51]; [@bib52]). We extracted lipidic species from *M. smegmatis* and exchanged endogenous [d]{.smallcaps}-alanines for biotin-[d]{.smallcaps}-lysine (BDL) in vitro using purified *Staphylococcus aureus* enzyme PBP4, a promiscuous [d]{.smallcaps},[d]{.smallcaps}-transpeptidase ([@bib51]). Biotinylated species were separated by SDS-PAGE and detected by horseradish peroxidase-conjugated streptavidin. We detected a biotin-linked, low-molecular-weight band that is reduced upon [d]{.smallcaps}-cycloserine treatment and accumulates when the lipid II flippase MurJ (MviN, ([@bib22])) is depleted or vancomycin is added ([Figure 5A](#fig5){ref-type="fig"}), conditions that have been shown to dramatically enhance precursor detection in other species ([@bib51]; [@bib52]). These data strongly suggest that the BDL-marked species are lipid-linked peptidoglycan precursors. We next turned our attention to detecting lipid I/II from *M. smegmatis* incubated with alkDADA. Initially we were unable to identify alkDADA-labeled species from organic extracts of wildtype *M. smegmatis* that had been subjected to CuAAC ligation with picolyl azide biotin ([Figure 5B](#fig5){ref-type="fig"}). We reasoned that the proportion of labeled precursors might be below our limit of detection. Accordingly, we repeated the experiment in the *Δalr* background and found that we could clearly detect a low molecular-weight species band that accumulated with vancomycin treatment ([Figure 5B](#fig5){ref-type="fig"}, top) and that ran at the same size as BDL-labeled material ([Figure 5B](#fig5){ref-type="fig"}, bottom). We were also able to identify a low-molecular-weight species from *Δalr* incubated with azDADA that was revealed by either CuAAC or SPAAC ligation to alkyne- or cyclooctyne-biotin, respectively ([Figure 5C](#fig5){ref-type="fig"}). Taken together, our genetic and biochemical experiments show that the alkDADA and azDADA probes insert into mycobacterial peptidoglycan precursors by a MurF-dependent route.

![alkDADA and azDADA incorporate into lipid-linked peptidoglycan precursors.\
(**A**) Detection of lipid-linked peptidoglycan precursors from organic extracts of *M. smegmatis*. Endogenous [d]{.smallcaps}-alanines (yellow) were exchanged for biotin-[d]{.smallcaps}-lysine (BDL; purple) via purified *S. aureus* PBP4. Biotinylated species detected by blotting with streptavidin-HRP. MurJ (MviN) depletion strain was incubated in anhydrotetracycline (atc) to induce protein degradation. Other strains were treated with vancomycin (vanc), [d]{.smallcaps}-cycloserine (dcs) or a combination prior to harvesting. Wt, wildtype; blank, no sample run; no extract, BDL and PBP4 alone ^a^, organic extract from MurJ - atc; ^b^, organic extract from MurJ + atc; hk, heat-killed. (**B**) Detection of lipid-linked peptidoglycan precursors labeled by alkDADA in vivo. Wildtype and *Δalr* strains were incubated in alkDADA (purple and yellow) and treated or not with the indicated antibiotics prior to harvest. Alkyne-tagged species from organic extracts were ligated to picolyl azide biotin via CuAAC then detected as in A. BDL/PBP4, endogenous precursors from MurJ + atc were subjected to in vitro exchange reaction as in A. (**C**) Detection of lipid-linked peptidoglycan precursors labeled by azDADA in vivo. Δalr was incubated in azDADA (purple and yellow). Azide-tagged species from organic extracts were ligated to DIFO-biotin via SPAAC, left, or to alkyne biotin via CuAAC, right, then detected as in A.\
10.7554/eLife.37243.030Figure 5---source data 1.Blots showing dipeptide probes in endogenous mycobacterial peptidoglycan precursors.](elife-37243-fig5){#fig5}

Fluorescent vancomycin and penicillin-binding proteins localize to the poles and sidewall in mycobacteria {#s2-4}
---------------------------------------------------------------------------------------------------------

The final, lipid-linked peptidoglycan precursor lipid II is synthesized by MurG on the cytoplasmic side of the plasma membrane then flipped to the periplasm and polymerized \[[Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}, ([@bib70])\]. We previously showed that MurG fused to two different fluorescent proteins and expressed under two different promoters is present at both the poles and periphery of *M. smegmatis* ([@bib44]). Labeling by alkDADA marks similar subcellular locations even with pulses as short as \~1% generation time ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). These data suggest that lipid-linked peptidoglycan precursors are synthesized at lateral sites in addition to their expected localization at the poles. However, our standard experimental protocol for detecting envelope labeling is to perform CuAAC on fixed cells. Because formaldehyde fixation can permeabilize the plasma membrane to small molecules, labeled material may be intracellular, extracellular or both. Dipeptide labeling could therefore read out lipid I/II on the cytoplasmic face of the plasma membrane, uncrosslinked lipid II on the periplasmic side, or polymerized peptidoglycan.

To shed light on the potential fate(s) of peptidoglycan precursors made at different subcellular sites, we first stained live mycobacterial cells with fluorescent vancomycin. This reagent binds uncrosslinked peptidoglycan pentapeptides and does not normally cross the plasma membrane. Pentapeptide monomers are a low abundant species in *M. tuberculosis*, *M. abscessus* and *M. leprae* peptidoglycan ([@bib33]; [@bib41]; [@bib36]; [@bib37]), suggesting that fluorescent vancomycin primarily reports extracellular, lipid-linked precursors in this genus. Labeling of *M. smegmatis* with this probe revealed both polar and lateral patches ([Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}) as previously noted ([@bib63]). This observation suggests that at least some of the peptidoglycan precursors present along the periphery of the mycobacterial cell are flipped to the periplasm.

We next sought to address whether these molecules could be used to build the peptidoglycan polymer. Transglycosylases from both the PBP (penicillin-binding proteins) and SEDS (shape, elongation, division, and sporulation) families stitch peptidoglycan precursors into the existing meshwork ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}, \[[@bib9]; [@bib25]; [@bib70]; [@bib14]; [@bib42]; [@bib38]; [@bib2]\]). If peptidoglycan precursors are polymerized along the lateral surface of the mycobacterial cell, at least a subset of these periplasmic enzymes must be present at the sidewall to assemble the biopolymer. Two conserved PBPs in mycobacteria are likely responsible for most of the peptidoglycan polymerization required for cell viability, PonA1 and PonA2 (7, 19, 59). Published images of PonA1-mRFP and PonA1-mCherry localization suggested that the fusion proteins might decorate the mycobacterial sidewall in addition to the cell tips ([@bib27]; [@bib26]; [@bib29]), but the resolution of the micrographs did not allow for definitive assignment. Therefore, we first verified the localization of PonA1-mRFP. We found that a subset of this fusion protein indeed homes to the lateral cell surface ([Figure 5---figure supplement 3A](#fig5s3){ref-type="fig"}).

We were concerned that overexpression of PonA1-mRFP causes aberrant polar morphology and is toxic to *M. smegmatis* ([@bib26]; [@bib29]) and about the propensity of mCherry to cluster ([@bib35]). Because our attempts to produce PonA1 fusions with different fluorescent proteins were unsuccessful, we opted to take a complementary, activity-based approach. Fluorescent derivatives of β-lactam antibiotics bind specifically and covalently to PBPs, and therefore have been used to image active enzyme in both protein gels and intact cells ([@bib32]). Our images of whole cells labeled with Bocillin, a BODIPY conjugate of penicillin, were in agreement with those from a previous publication ([@bib49]), and seemed to indicate that Bocillin binds both the poles and sidewall of *M. smegmatis* ([Figure 5---figure supplement 3B and C](#fig5s3){ref-type="fig"}). However, given the hydrophobicity of the BODIPY dye, we considered the possibility that Bocillin might nonspecifically associate with the greasy mycomembrane. Fluorescence across the cell surface was diminished by pre-treating cells with the β-lactam ampicillin, which prevents peptidoglycan assembly by binding to PBPs, but not [d]{.smallcaps}-cycloserine, which inhibits peptidoglycan synthesis in a PBP-independent manner ([Figure 5---figure supplement 3B and C](#fig5s3){ref-type="fig"}). These experiments suggest that at least some of the sidewall labeling of Bocillin is specific, and therefore, that PBPs are present and active in these locations.

Expansion of the mycobacterial envelope is concentrated at the poles {#s2-5}
--------------------------------------------------------------------

Our data indicate that peptidoglycan precursors are made and likely polymerized both at the poles and sidewall. Peptidoglycan synthesis is often presumed to mark sites of bacterial cell growth. However, dispersed elongation has not been reported in mycobacteria. Accordingly we performed a pulse chase experiment to test whether cell expansion correlates with sites of metabolic labeling. After marking peptidoglycan with RADA, we tracked labeled and unlabeled cell surface during 15 min (\~10% generation time) of outgrowth. While we cannot rule out sidewall expansion below our limit of detection, the fluorescence dilution in this experiment was consistent with previous reports ([@bib1]; [@bib57]; [@bib44]; [@bib31]; [@bib9]; [@bib54]) and restricted to the mycobacterial poles ([Figure 5---figure supplement 4](#fig5s4){ref-type="fig"}).

Muramidase treatment increases peptidoglycan synthesis along the sidewall {#s2-6}
-------------------------------------------------------------------------

What is the function of peptidoglycan assembly that does not directly contribute to physical expansion of the cell? We hypothesized that one role of growth-independent cell wall synthesis might be repair. More specifically, we reasoned that insertion of peptidoglycan building blocks directly along the cell periphery would enable a real-time, comprehensive response to damage ([Figure 6A](#fig6){ref-type="fig"}). Cell wall repair that is restricted to sites of mycobacterial growth, by contrast, would be confined to the poles and renew the cell surface only after several generations. Extended incubation of *M. smegmatis* (\~48 hr) with the peptidoglycan-degrading enzyme lysozyme substantially decreases colony-forming units ([@bib28]). We have also shown that spheroplasts generated by combined glycine and lysozyme treatment lack peptidoglycan ([@bib43]). Together these data indicate that the enzyme is able to access and damage peptidoglycan in intact cells. We challenged *M. smegmatis* for 30 min in a mixture of lysozyme and mutanolysin, another enzyme that has been extensively used for in vitro digestion of peptidoglycan. After washing away the enzyme, we assessed the sites of peptidoglycan synthesis by alkDADA labeling. Pre-treatment by the muramidases clearly shifted the fluorescence from the brighter pole towards the sidewall ([Figure 6B](#fig6){ref-type="fig"}). These data indicate that mycobacteria reallocate peptidoglycan assembly away from the faster growing pole and toward the periphery upon damage to the cell wall ([Figure 6A](#fig6){ref-type="fig"}).

![Peptidoglycan synthesis is redistributed to the sidewall upon cell wall damage.\
(**A**) Model for the spatial organization of peptidoglycan (PG) synthesis and repair with respect to mycobacterial growth and division. Left, regions of cell surface that expand are highlighted in blue. Middle and right, areas of peptidoglycan precursor synthesis are highlighted in orange. (**B**) *M. smegmatis* was pretreated (dark green) or not (light green) with lysozyme (lys) and mutanolysin (mut) for 30 min then incubated an additional 15 min in the presence of alkDADA. The bacteria were then washed and fixed and subjected to CuAAC with azido-CR110. Fluorescence was quantitated as in [Figure 2](#fig2){ref-type="fig"} for cells without (top; 232 \< n \< 236) and with (bottom; 29 \< n \< 55) visible septa. Dim pole (dp), sidewall (sw) and bright pole (bp) defined as in [Figure 2](#fig2){ref-type="fig"}. Fluor distrib, average fluorescence distribution. AU, arbitrary units. Error bars, ±standard deviation. Statistical significance between untreated (four biological replicates) and lysozyme/mutanolysin-treated (three biological replicates) was assessed for the dim pole, sidewall and bright pole by two-tailed Student's t test. \*p\<0.05; \*\*p\<0.005.\
10.7554/eLife.37243.032Figure 6---source data 1.Conventional fluorescence microscopy images of *M. smegmatis* challenged with peptidoglycan-digesting enzymes.](elife-37243-fig6){#fig6}

Discussion {#s3}
==========

In this work, we aimed to address the seemingly discrepant observations that, on the one hand, mycobacteria expand from their tips ([Figure 5---figure supplement 4](#fig5s4){ref-type="fig"}, \[[@bib1]; [@bib57]; [@bib44]; [@bib31]; [@bib9]\]), and on the other, metabolically labeled cell wall and synthetic enzymes are detectable at both the poles and along the sidewall ([Figure 5---figure supplement 3](#fig5s3){ref-type="fig"} \[[@bib44]; [@bib27]; [@bib26]; [@bib29]; [@bib49]\]). The first step to resolving this conundrum was to unambiguously identify sites of peptidoglycan synthesis. Although the [d]{.smallcaps}-amino acid probes that we and others have developed for peptidoglycan labeling have been extensively used for marking the cell wall ([@bib62]), in most cases it has not been clear whether they report the location(s) of cytoplasmic synthesis, periplasmic exchange, or a combination of processes. Here, we show that in *M. smegmatis* the metabolic fate of monopeptide probes is partially dependent on the substituent; whereas NBD and TAMRA-conjugated [d]{.smallcaps}-amino acids are primarily exchanged into mycobacterial peptidoglycan by [l]{.smallcaps},[d]{.smallcaps}-transpeptidases, their alkyne and coumarin-conjugated counterparts appear to incorporate by both extracellular and intracellular pathways ([Figure 3](#fig3){ref-type="fig"}). In the future, biochemical analysis of peptidoglycan composition will allow better quantitation of probe incorporation via different uptake pathways ([@bib13]).

We show that dipeptide probes rescue the growth of a DdlA mutant ([Figure 4B](#fig4){ref-type="fig"}) and incorporate into lipid-linked peptidoglycan precursors ([Figure 5B and C](#fig5){ref-type="fig"}). To our knowledge, this is the first direct demonstration that peptidoglycan precursors can be metabolically labeled in vivo without radioactivity. Labeling by alkDADA unexpectedly decreased in the absence of [l]{.smallcaps},[d]{.smallcaps}-transpeptidases ([Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}). Unlike the monopeptide probes, however, alkDADA-derived fluorescence was stable to pre-treatment with imipenem, an antibiotic that targets this class of enzymes ([Figure 3](#fig3){ref-type="fig"}, \[[@bib33]\]). These data suggest that the dipeptide is unlikely to be a direct substrate for [l]{.smallcaps},[d]{.smallcaps}-transpeptidases. It is possible that [d,d-]{.smallcaps}carboxypeptidases cleave a small proportion of alkDADA prior to incorporation and release [d]{.smallcaps}-alanine and alkDA. In this scenario, apparent alkDADA labeling in *M. smegmatis* may be a combination of intracellular alkDADA incorporation via MurF ([Figures 4](#fig4){ref-type="fig"} and [5](#fig5){ref-type="fig"}), extracellular alkDA incorporation by [l]{.smallcaps},[d]{.smallcaps}-transpeptidases ([Figure 3](#fig3){ref-type="fig"}), and more limited intracellular alkDA incorporation by DdlA/MurF ([Figure 3](#fig3){ref-type="fig"}). This model is consistent with the promiscuous targeting of mycobacterial [d,d-]{.smallcaps}carboxypeptidases by carbapenems ([@bib33]) and the \~2000 fold more efficient incorporation of alkDA compared to alkDADA ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). Alternatively or additionally, alkDADA may be degraded abiotically or by other enzymes such as [l,d]{.smallcaps}-carboxypeptidases. Finally, loss of [l]{.smallcaps},[d]{.smallcaps}-transpeptidases may introduce global alterations in peptidoglycan metabolism. Importantly, despite differences in overall fluorescence between dipeptide-labeled wild-type and Δ*ldtABE* ([Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}), sidewall fluorescence was preserved in the mutant ([Figure 4---figure supplement 1B](#fig4s1){ref-type="fig"}). In aggregate our data strongly suggest that the mycobacterial periphery is a site of active peptidoglycan synthesis.

The lateral surface of mycobacteria does not appear to contribute to cell elongation under normal growth conditions ([Figure 5---figure supplement 4](#fig5s4){ref-type="fig"}, \[[@bib1]; [@bib57]; [@bib44]; [@bib31]; [@bib9]\]) but nevertheless hosts a substantial portion of envelope synthesis and remodeling. The intracellular difference in signal between the poles reflected relative elongation rates, as the RADA-bright cell tip, which coincides with the alkDADA- and OalkTMM-bright cell tip ([Figure 2B](#fig2){ref-type="fig"}) grows faster than the RADA-dim cell tip ([Figure 5---figure supplement 4](#fig5s4){ref-type="fig"}). The twofold ratio of fast/bright:slow/dim pole fluorescence ([Figures 2C, D](#fig2){ref-type="fig"} and [6B](#fig6){ref-type="fig"}) roughly corresponds to previous estimates of intracellular differences in polar elongation ([@bib1]; [@bib27]). Compared to *M. smegmatis*, the distribution of HADA labeling in *M. tuberculosis* is shifted away from the fast pole toward the periphery ([Figure 2D](#fig2){ref-type="fig"}). Diminished polarity and asymmetry is also apparent in the sub-population of *M. tuberculosis* that is labeled by alkDADA and OalkTMM ([Figure 2---figure supplement 2C](#fig2s2){ref-type="fig"}). Our data are in agreement with the heterogeneity in polar dominance observed previously for *M. tuberculosis* ([@bib8]). Although we cannot rule out a contribution from cyan autofluorescence, these experiments also suggest that sidewall envelope metabolism may be even more prominent in *M. tuberculosis* than in *M. smegmatis*, comprising 70--75% of the total cell output.

It is possible that peptidoglycan assembly along the lateral surface of the mycobacterial cell is simply a byproduct of synthetic enzymes that are en route to the polar elongasome or the divisome. Having active enzymes at the ready could enable efficient coordination between cell growth and septation. We think that this model is less likely, however, given the energetic cost of producing complex macromolecules and the known limits on the steady-state pools of lipid-linked peptidoglycan precursors ([@bib67]). Instead we propose that cell wall synthesis along the periphery could allow mycobacteria to edit what would otherwise be an inert surface ([Figure 6A](#fig6){ref-type="fig"}). Peptidoglycan and mycomembrane metabolism in this region may thicken or fill in the gaps of envelope that was initially deposited at the poles or the septum and enable the bacterium to correct stochastic defects and repair damage. In support of this model, we find that cell wall synthesis along the sidewall is enhanced upon exposure to peptidoglycan-degrading enzymes ([Figure 6B](#fig6){ref-type="fig"}). More broadly, the ability to tailor the entire cell surface, not just the ends, should enable rapid adaptation to external stimuli. Such activity may be particularly important for *M. tuberculosis*, a slow-growing organism that must survive a hostile, nutrient-poor environment.

Materials and methods {#s4}
=====================

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type (species)\   Desig-nation                                                              Source or reference                  Identifiers          Additional information
  or resource                                                                                                                                                   
  ------------------------- ------------------------------------------------------------------------- ------------------------------------ -------------------- --------------------------------------------------
  Strain\                   *M. smegmatis*                                                            NC_008596 in GenBank                                      Wildtype *M. smegmatis*
  (*M. smegmati*s mc2155)                                                                                                                                       

  Genetic reagent\          *∆alr*                                                                    This paper                                                The mutant was generated by recombineering\
  (*M. smegmatis*)                                                                                                                                              protocols described in DOI: 10.1038/nmeth996\
                                                                                                                                                                and DOI: 10.1007/978-1-4939-2450-9_10;\
                                                                                                                                                                see the methods section for further detail.

  Genetic reagent\          *ΔldtA*                                                                   doi:10.1101/291823                                        Obtained from Dr. Eric Rubin (Harvard SPH)\
  (*M. smegmatis*)                                                                                                                                              and Dr. Hesper Rego (Yale Med)

  Genetic reagent\          *ΔldtB*                                                                   doi:10.1101/291823                                        Obtained from Dr. Eric Rubin (Harvard SPH)\
  (*M. smegmatis*)                                                                                                                                              and Dr. Hesper Rego (Yale Med)

  Genetic reagent\          *ΔldtE*                                                                   doi:10.1101/291823                                        Obtained from Dr. Eric Rubin (Harvard SPH)\
  (*M. smegmatis*)                                                                                                                                              and Dr. Hesper Rego (Yale Med)

  Genetic reagent\          *ΔldtAE*                                                                  doi:10.1101/291823                                        Obtained from Dr. Eric Rubin (Harvard SPH)\
  (*M. smegmatis*)                                                                                                                                              and Dr. Hesper Rego (Yale Med)

  Genetic reagent\          *ΔldtBE*                                                                  doi:10.1101/291823                                        Obtained from Dr. Eric Rubin (Harvard SPH)\
  (*M. smegmatis*)                                                                                                                                              and Dr. Hesper Rego (Yale Med)

  Genetic reagent\          *ΔldtBA*                                                                  doi:10.1101/291823                                        Obtained from Dr. Eric Rubin (Harvard SPH)\
  (*M. smegmatis*)                                                                                                                                              and Dr. Hesper Rego (Yale Med)

  Genetic reagent\          *ΔldtABE*                                                                 doi:10.1101/291823                                        Obtained from Dr. Eric Rubin (Harvard SPH)\
  (*M. smegmatis*)                                                                                                                                              and Dr. Hesper Rego (Yale Med)

  Genetic reagent\          MurJ (MviN)                                                               doi: 10.1126/scisignal.2002525.                           Obtained from Dr. Chris Sassetti (U Mass Med)
  (*M. smegmatis*)                                                                                                                                              

  Genetic reagent\          *ddlAts*                                                                  doi: 10.1128/JB.182.23.\                                  Obtained from Dr. Graham Hatfull (U Pitt)
  (*M. smegmatis*)                                                                                    6854--6856.2000                                           

  Genetic reagent\          *pTetOldtA*                                                               doi: 10.1101/291823                                       Obtained from Dr. Eric Rubin (Harvard SPH)\
  (*M. smegmatis*)                                                                                                                                              and Dr. Hesper Rego (Yale Med)

  Genetic reagent\          *ΔRD1 ΔpanCD*                                                             doi: 10.1016/j.vaccine.2006.05.097                        Obtained from Dr. Bill Jacobs (Einstein Med)
  (*M. tuberculosis*)                                                                                                                                           

  Other                     RADA                                                                      doi: 10.1002/anie.201206749;\                             Synthesized by Tocris Bioscience (Bristol,\
                                                                                                      doi: 10.1038/nprot.2014.197                               United Kingdom) following referenced protocols

  Other                     NADA                                                                      doi: 10.1002/anie.201206749;\                             Synthesized by Tocris Bioscience (Bristol,\
                                                                                                      doi: 10.1038/nprot.2014.197                               United Kingdom) following referenced protocols

  Other                     HADA                                                                      doi: 10.1002/anie.201206749;\                             Synthesized by Tocris Bioscience (Bristol,\
                                                                                                      doi: 10.1038/nprot.2014.197                               United Kingdom) following referenced protocols

  Other                     alkyne-[d]{.smallcaps}-alanine\                                           Thermo Fisher, Waltham, MA           Cat \# AC441225000   
                            (alkDA;EDA)                                                                                                                         

  Other                     alkyne-[d]{.smallcaps}-alanine-[d]{.smallcaps}-alanine (alkDADA; EDADA)   doi: 10.1038/nature12892                                  Synthesized by the Chemical Synthesis Core\
                                                                                                                                                                Facility at Albert Einstein College of Medicine\
                                                                                                                                                                (NY, USA) following the referenced protocols

  Other                     azido-[d]{.smallcaps}-alanine-[d]{.smallcaps}-alanine (azDADA; ADADA)     doi: 10.1038/nature12892                                  Synthesized by the Chemical Synthesis Core\
                                                                                                                                                                Facility at Albert Einstein College of Medicine\
                                                                                                                                                                (NY, USA) following the referenced protocols

  Other                     O-alkyne-trehalose\                                                       doi: 10.1002/anie.201509216                               
                            monomycolate (OalkTMM)                                                                                                              

  Other                     N-alkyne-trehalose\                                                       doi: 10.1002/anie.201509216                               
                            monomycolate (NalkTMM)                                                                                                              

  Software, algorithm       MATLAB codes                                                              This paper                                                Scripts designed for MATLAB to analyze\
                                                                                                                                                                the fluorescence profiles along a cell\
                                                                                                                                                                body from data collected in Oufti\
                                                                                                                                                                (doi: 10.1111/mmi.13264).

  Chemical compound, drug   Fmoc-D-Lys(biotinyl)-\                                                    Chem-Impex International             Cat \# 16192         Deprotected as described in\
                            OH (BDL precursor)                                                                                                                  doi: 10.1021/ja508147s to yield BDL

  DNA reagent               PBP4 plasmid                                                              doi: 10.1021/ja508147s                                    Obtained from Dr. Suzanne Walker (Harvard Med)
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Bacterial strains and culture conditions {#s4-1}
----------------------------------------

mc^2^155 *M. smegmatis* and Δ*RD1* Δ*panCD M. tuberculosis* ([@bib56]) were grown at 37°C in Middlebrook 7H9 growth medium (BD Difco, Franklin Lakes, NJ) supplemented with glycerol, Tween 80 and ADC (*M. smegmatis*) or OADC and 50 µg/ml pantothenic acid (*M. tuberculosis*). The ∆*alr* strain was further supplemented with 1 mM [d]{.smallcaps}-alanine. The *ddlA^ts^* strain was grown in 7H9-ADC at 30°C or 37°C as specified.

Cell envelope labeling {#s4-2}
----------------------

Probes used in this study include (i) fluorescent [d]{.smallcaps}-amino acids HADA, NADA and RADA (Tocris Bioscience, Bristol, UK) (ii) alkDA (R-propargylglycine, Thermo Fisher, Waltham, MA) (iii) alkDADA and azDADA (Chemical Synthesis Core Facility, Albert Einstein College of Medicine, Bronx, NY) and (iv) OalkTMM and NalkTMM, synthesized as described previously ([@bib21]). The labeling procedures were performed with modifications from ([@bib34]; [@bib61]; [@bib21]). Unless otherwise indicated, mid-log *M. smegmatis* or *M. tuberculosis* were labeled with 500 μM HADA, 25 μM NADA or RADA, 50 μM alkDA, 1 or 2 mM alkDADA, 50 μM OalkTMM or 250 μM NalkTMM for 15 min or 2 hr, respectively. In some cases *M. smegmatis* was preincubated ± antibiotics at different fold-MIC (MICs = 80 μg/mL [d]{.smallcaps}-cycloserine, 8 μg/mL ampicillin (with 5 μg/mL clavulanate), 0.5 μg/mL imipenem (with 5 μg/mL clavulanate), 6 μg/mL vancomycin) or ± 500 µg/mL lysozyme and 500 U/mL mutanolysin for 30 min then grown for an additional 15 min in the presence of the probes. Cultures were then centrifuged at 4°C, washed in pre-chilled PBS containing 0.05% Tween 80% and 0.01% BSA (PBSTB) and fixed for 10 min in 2% formaldehyde at room temperature (RT). After two washes in PBSTB, the bacterial pellets were resuspended in half of the original volume of freshly prepared CuAAC solution in PBSTB ([@bib61]) containing either AF488 picolyl azide or carboxyrhodamine 110 (CR110) azide (Click Chemistry Tools, Scottsdale, AZ) or 3-azido-7-c (Jena Biosciences, Jena, Germany). For *M. tuberculosis* experiments and in [Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}, we used a modified, low-copper CuAAC reaction protocol: 200 μM CuSO~4~ and 800 μM BTTP (Chemical Synthesis Core Facility, Albert Einstein College of Medicine, Bronx, NY) were pre-mixed then added to PBSTB. Immediately before resuspending the pellets, 2.5 mM freshly prepared sodium ascorbate and 300 μM 3-azido-7-hydroxycoumarin were added to the mixture. After 30--60 min gentle agitation at RT, cultures were washed once with PBSTB, once with PBS and resuspended in PBS for imaging or flow cytometry analysis (FITC, BV510, and Texas Red channels on a BD DUAL LSRFortessa, UMass Amherst Flow Cytometry Core Facility). NHS ester dye labeling and fluorescent vancomycin labeling were performed as described ([@bib1]; [@bib66]). *M. tuberculosis* was post-fixed with 4% formaldehyde overnight at RT prior to removing from the biosafety cabinet. For Bocillin labeling experiments, 500 μL of mid-log *M. smegmatis* was washed once in PBST and resuspended in PBST containing 5 μg/mL clavulanate. Bacteria were then pre-incubated or not with 50 μg/mL ampicillin or [d]{.smallcaps}-cycloserine at RT with gentle agitation. After 15 min, 50 μg/mL Bocillin FL (Thermo Fisher) was added and cultures were incubated for an additional 30 min. They were then washed three times in PBST and imaged live on agar pads.

Genetic manipulation {#s4-3}
--------------------

The *Δalr M. smegmatis* strain was generated using standard recombineering methods ([@bib68]; [@bib45]). 500 bp up- and downstream of *alr* were cloned on either side of the *hyg^R^* cassette flanked with *loxP* sites. After induction of *recET*, transformation and subsequent selection on hygromycin and 1 mM [d]{.smallcaps}-alanine, PCR was used to confirm the presence of the correct insert. Strains were then cured of the *hyg^R^* cassette by transformation with an episomal plasmid carrying the Cre recombinase and a sucrose negative selection marker. Strains were cured of this plasmid by repeated passaging in the presence of sucrose.

*M. smegmatis* lacking *ldtA, ldtB* and/or *ldtE* were generously provided by Dr. Kasia Baranowski, Dr. Eric Rubin and Dr. Hesper Rego and are described in bioRxiv <https://doi.org/10.1101/291823.> Briefly, strains were constructed by recombineering to replace the endogenous copies with zeocin or hygromycin resistance cassettes flanked by *loxP* sites as previously described above ([@bib9]). Once the knock-outs were verified by PCR, the antibiotic resistance cassettes were removed by the expression of Cre recombinase. To complement Δ*ldtABE,* a copy of *ldtA* was under the constitutive TetO promoter on a kanamycin marked vector (CT94) that integrates at the L5 phage integration site of the chromosome.

Microscopy {#s4-4}
----------

Fixed bacteria were imaged either by conventional fluorescence microscopy (Nikon Eclipse E600, Nikon Eclipse Ti or Zeiss Axioscope A1 with 100x objectives) or by structured illumination microscopy (Nikon SIM-E/A1R with SR Apo TIRF 100x objective).

Microscopy analysis {#s4-5}
-------------------

Images were processed using FIJI ([@bib59]) and cells were outlined and segmented using Oufti ([@bib47]). Fluorescence signals of each cell were detected using Oufti and analyzed using custom-written MATLAB codes. The fluorescence intensities that we report here have been normalized by cell area. We distinguished septating from non-septating cells using the probe fluorescence profile along the long cell axis. We used the peakfinderprogram ([@bib64]) to identify peaks in the labeling profile. Because our probes label both the cell poles as well as the septum, septating cells were those that had three peaks in their labeling profile, with the middle peak positioned between 30% and 70% along the normalized long cell axis. Non-septating cells were identified as having only two peaks.

Detection of lipid-linked peptidoglycan precursors {#s4-6}
--------------------------------------------------

To detect endogenous lipid-linked peptidoglycan precursors, we adopted the assay developed in ([@bib51]) with some modifications. *M. smegmatis* was inoculated in 100 mL of 7H9 medium and grown to mid-log phase at 37°C. Where applicable, MurJ was depleted by 8 hr of anhydrotetracycline-induced protein degradation as described ([@bib22]). The bacteria were then divided into 25 mL cultures that were subjected or not to freshly prepared 80 µg/mL vancomycin and/or 10 µg/mL [d]{.smallcaps}-cycloserine. After 1 hr of incubation at 37°C, bacteria were collected by centrifugation and cell pellets were normalized by wet weight. 200--300 mg wet pellet was resuspended in 500 µL 1% glacial acetic acid in water. 500 µL of the resuspended pellet mixture was transferred into a vial containing 500 µL of chloroform and 1 mL of methanol and kept at room temperature (RT) for 1--2 hr with occasional vortexing. The mixture was then centrifuged at 21,000x g for 10 min at RT and the supernatant was transferred into a vial containing 500 µL of 1% glacial acetic acid in water and 500 µL chloroform, and vortexed for 1 min. After centrifugation at 900x g for 2 min at RT, three phases were distinguishable: aqueous, an interface, and organic. We collected the lipids from the organic phase and from the interface and concentrated it under nitrogen. Organic extracts were resuspended in 12 µL of DMSO and then incubated with purified *S. aureus* PBP4 and biotin-[d]{.smallcaps}-lysine (BDL; deprotected from Fmoc-D-Lys(biotinyl)-OH; Chem-Impex International) as described ([@bib51]). Upon completion of the BDL exchange reaction, 10 µL of 2X loading buffer was added to the vials. Contents were boiled at 95°C for 5 min then run on an 18% SDS polyacrylamide gel. Biotinylated species were transferred to a PVDF membrane, blotted with streptavidin-HRP (diluted 1:10,000, Thermo-Fisher) and visualized in an ImageQuant system (GE Healthcare).

To detect lipid-linked precursors that had been metabolically labeled with alkDADA or azDADA, growth of the *Δalr* strain was initially supported by the inclusion of 2 mM [d]{.smallcaps}-alanine-[d]{.smallcaps}-alanine (Sigma-Aldrich) in the 7H9 medium. *Δalr* bacteria were harvested and washed twice in sterile PBST prior to resuspension in 100 mL of pre-warmed medium. Both wildtype and *Δalr M. smegmatis* were incubated in 0.5--1 mM of alkDADA or azDADA for 1 hr then harvested as described above. Organic extracts from metabolically labeled cultures were subjected to CuAAC reaction by adding, in order and in a non-stick vial: 2 µL of PBST, 1 µL of 5 mM CuSO~4~, 1 µL of 20 mM BTTP, 1 µL of freshly-prepared 50 mM sodium ascorbate, 3 µL of 10 mM picolyl azide biotin or alkyne biotin (Click Chemistry Tools), and 2 µL of the organic extract. The reaction was incubated for 1 hr at RT with gentle shaking prior to detecting as above.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Sidewall cell envelope synthesis and remodeling in pole-growing mycobacteria\" for consideration by *eLife*. Your article has been reviewed Gisela Storz as the Senior Editor, a Reviewing Editor, and three reviewers. The following individual involved in review of your submission has agreed to reveal her identity: Bree Aldridge (Reviewer \#2).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

Current views of mycobacterial cell growth dictate that these organisms primarily expand and remodel their cell surfaces at the polar regions. This is facilitated by an elongasome complex, comprising a tropomyosin-like protein (DivIVA), which forms a multiprotein complex with cell wall biosynthetic enzymes to allow for insertion of new cell wall material in the sub-polar region of the cell tip. The assumption in this case has been that side wall remodeling does not occur and that this region of the cell wall is inert. The submission by Siegrist and colleagues undertakes a detailed investigation of whether remodeling of the peptidoglycan (PG) layer occurs along the lateral axis of the mycobacterial cell. They hypothesize that if side-wall PG is not inert, enzymes should be present to allow for remodeling in this region. To test this, they first localize PonA1 (a HMW PBP) in Mycobacterium smegmatis and show that notable side wall localization occurs, further confirmed by using a BODIPY conjugate of penicillin (bocillin), that should bind HMW PBPs. Side wall binding by bocillin was abrogated with ampicillin treatment, confirming the association of the conjugate with PBPs. The authors confirm these observations by using metabolic probes, which included derivatives of D-amino acids and report bidirectional gradients of fluorescence, emanating from the cell pole and weakened towards mid-cell. Similar patterns were observed with trehalose probes that label mycolic acids, confirming that biosynthesis of the various layers in the mycobacterial envelope are spatially coordinated. Next, the authors sought to test whether similar staining patterns prevail in *M. tuberculosis* however, uptake of the probes was poor, with a high degree of heterogeneity. After some optimization, the population of cells that stained had a mixture of polar and side wall labeling. By comparing the ratios of staining intensities at the pole versus the side-wall the authors suggest that in mycobacteria, a notable proportion of PG labeling by probes occurs on the sidewall. Using a pulse chase experiment with RADA, the authors demonstrate that fluorescence dilution is asymmetric. After this, the authors sought to assess how D-amino acid probes are incorporated into mycobacterial PG by selectively inhibiting cytoplasmic and periplasmic steps pf PG synthesis using antibiotics. La belling with single D-amino acids was reduced with antibiotics that target either the cytoplasmic or periplasmic incorporation of these probes. In contrast, labeling with the dipeptide (alkDADA) was unaffected. To test the role of L,D-transpeptidase (Ldts) in probe incorporation, the authors deleted three of the six putative Ldts in M smegmatis (ΔldtABE) and demonstrated a reduction in probe uptake. Next, the authors report that the dipeptide probe labelled cells with reduced efficiency when compared to the single amino acid forms. To further study this, the authors abrogate alanine racemase activity, which should eliminate de novo synthesis of the dipeptide. The resulting mutant could be rescued with exogenous D-ala-D-ala supplementation, confirming the role of MurF in incorporating this alkDADA probe, further evidenced by isolation of lipid-linked, labelled derivatives. Finally, the authors demonstrate that alkDADA labeling can be modulated by treatment with imipenem.

Central conclusions:

1\) Notable sidewall remodeling of PG occurs in mycobacteria, linked to the activity of PBPs

2\) Incorporation of the alanine derivatives, but not the dipeptide probe (alk-DADA) is inhibited by Imipenem

3\) Alk-DADA can rescue the growth of a D-alanine racemase and ligase mutants

4\) Alk-DADA is incorporated into LipidII in vivo.

Overall, this is an interesting story, with novel finding regards how probes, which are now becoming more widely used in the field, are being incorporated into the PG polymer.

Essential revisions:

1\) Some aspects of the statistics should be sharpened or added. Figure 2 -- An argument for additivity is not most effectively made with a t-test. In this case, seeing that the drugs in combination are used at the same concentration as they are alone, a probabilistic model (e.g. Bliss scoring) should be used instead. For example, amp does not impede labeling alone, so it is actually additive with imi, as the amount labeled together is almost the same as imi alone. If labeling on two drugs independently is reduced to 50% each, for example, then if they act independently (additive), the combination should label at a reduction of 75%. Rescoring this will strengthen the argument of this section. Figure 3 -- Because these measurements were taken together, ANOVA and posthoc tests would be more appropriate than t tests on the pairs. Also, in this figure, the statistical analysis seems to be based on both biological and technical replicates. This is misleading, only biological replicates should be used for the statistics. Figure 5 -- the bar plots could use some statistical testing

2\) Reviewers raised concerns regards the relevance of side-wall labeling. Please address this. An experiment that highlights the relevance/importance of sidewall labelling in mycobacteria would enhance the impact of your manuscript. What is the physiological importance of sidewall labeling to growth or survival?

3\) Related to point 2 above, although the imaging findings in Figure 1 do clearly show sidewall labelling, some clarification of the interpretation of this finding is needed. Because the signal is a gradient from the bright pole labelling to the sidewall, it seems possible that the labelled cell wall appears on the sidewall is due to movement from the pole based on growth, rather than in situ labelling. The labelling time is short, possibly arguing against this possibility, but some clarification is required. Optimally, time-lapse experiments could address this issue, but they may be challenging given the need for fixation for probe visualization. Please comment on this issue and potentially design experiments to address this concern.

4\) The data in Figure 5 lack clarity. It is not clear how this finding contributes to the paper and how the interpretation of \"stabilization\" of the probe by B-lactam treatment adds to the model or modifies the interpretation of the prior figures. Please consider this point and integrate these observations more carefully into your manuscript.

5\) Antibiotic titrations for labeling experiments would strengthen some observations. Is it possible that in the imipenem treated cells, destabilization of PG, and cell death is affecting probe uptake? Please address the issue of whether probe uptake is affected by cell death.

6\) Importantly, all reviewers have raised concerns with the way you have compiled and presented your manuscript. Two main issues that emerged are (I) this seems like an amalgamation of two stories (side wall labeling) and (FDAA probe uptake and related findings) and (II) the manuscript is hard to follow. Please give these comments careful attention when revising your manuscript. It would seem that the major focus of the manuscript is how FDAAs are taken up in mycobacteria. Perhaps you can start your manuscript with this aspect, develop it carefully using appropriate figures and models. Thereafter, you can discuss how the enhanced understanding of FDAAs developed in the manuscript assists with dissecting sidewall labeling. Revise your introduction and discussion (which is currently unnecessarily long) sections appropriately. Perhaps the title needs some reconsideration, to capture the revised focus of the manuscript. Due to the interdisciplinary nature of the work, additional schematics and summary figures would be helpful (in the manner done for Figure 2A). An information box re the chemistry would also help readability and would provide a format to highlight what is learned about these labels. There are some sections that could be moved to supplementary information to help streamline the results (such as Bocillin labeling, vanc staining, and some detail about polar elongation).
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Author response

> Essential revisions:
>
> 1\) Some aspects of the statistics should be sharpened or added. Figure 2 -- An argument for additivity is not most effectively made with a t-test. In this case, seeing that the drugs in combination are used at the same concentration as they are alone, a probabilistic model (e.g. Bliss scoring) should be used instead. For example, amp does not impede labeling alone, so it is actually additive with imi, as the amount labeled together is almost the same as imi alone. If labeling on two drugs independently is reduced to 50% each, for example, then if they act independently (additive), the combination should label at a reduction of 75%. Rescoring this will strengthen the argument of this section.

We have consulted with a colleague in the UMass Amherst statistics department (now in the Acknowledgements section) to improve our analyses.

We first performed titration experiments to gauge the effects of ampicillin, imipenem and Dcycloserine on alkDA incorporation (see also Essential revision \#5). Probe incorporation was not impacted by ampicillin at any of the doses. We next assessed the interaction between imipenem and D-cycloserine by the Bliss independence model. The titrations and rescored data are now in Figures 3C and 3D and the accompanying legend and text.

> Figure 3 -- Because these measurements were taken together, ANOVA and posthoc tests would be more appropriate than t tests on the pairs. Also, in this figure, the statistical analysis seems to be based on both biological and technical replicates. This is misleading, only biological replicates should be used for the statistics.

We have done an ANOVA followed by Dunnett's test on the biological replicates. Please see revised Figure 4 (formerly Figure 3) and accompanying legend.

> Figure 5 -- the bar plots could use some statistical testing

We have done an ANOVA on the log~10~-transformed data from the biological replicates for Figure 4---figure supplement 2 (formerly Figure 5A). The rest of the data from this figure has been removed (see also Essential revision \#4).

> 2\) Reviewers raised concerns regards the relevance of side-wall labeling. Please address this. An experiment that highlights the relevance/importance of sidewall labelling in mycobacteria would enhance the impact of your manuscript. What is the physiological importance of sidewall labeling to growth or survival?

In the revised manuscript we now show that lysozyme/mutanolysin treatment increases sidewall dipeptide labeling in *M. smegmatis*. The fluorescence is also more symmetric. We would not expect cell wall damage from muramidases (or other insults) to be limited to the poles and consequently hypothesize that pole-growing organisms must have the ability to monitor and repair the entire cell surface. Please see Figure 6 and accompanying text for more details.

> 3\) Related to point 2 above, although the imaging findings in Figure 1 do clearly show sidewall labelling, some clarification of the interpretation of this finding is needed. Because the signal is a gradient from the bright pole labelling to the sidewall, it seems possible that the labelled cell wall appears on the sidewall is due to movement from the pole based on growth, rather than in situ labelling. The labelling time is short, possibly arguing against this possibility, but some clarification is required. Optimally, time-lapse experiments could address this issue, but they may be challenging given the need for fixation for probe visualization. Please comment on this issue and potentially design experiments to address this concern.

This is what we initially assumed! Movement of the poles may explain some of the brighter sub-polar labeling but we don't think it can account for labeling that occurs closer to the center of the cell. The original experiments were performed using 15 min pulses of probe incubation, or approximately \~8-10% of *M. smegmatis* generation time. Our pulse chase experiment with RADA labeling (Figure 5---figure supplement 4) illustrates that there is limited movement of the poles in that time frame.

The ideal experiment would be to perform time-lapse imaging with turn-on dipeptide probes to observe incorporation in real time. Unfortunately to our knowledge such reagents have not yet been published. To address the pole movement concern, we instead repeated alkDADA labeling with very short, 2 min pulses (\~1% of generation time). We still observe sidewall labeling in addition to the expected polar fluorescence (Figure 5---figure supplement 1).

> 4\) The data in Figure 5 lack clarity. It is not clear how this finding contributes to the paper and how the interpretation of \"stabilization\" of the probe by B-lactam treatment adds to the model or modifies the interpretation of the prior figures. Please consider this point and integrate these observations more carefully into your manuscript.

The sensitivity of dipeptide labeling to L,D-transpeptidation does not add to our model of sidewall peptidoglycan synthesis in mycobacteria, nor does it change the interpretation of prior figures.

Adding to an already-complicated story, we recently found that imipenem treatment and *ldtE* mutation respectively increase and decrease the abundance of BDL-detectable, lipid-linked precursors. The *ldtE* phenotype is complemented by reintroduction of the gene. While this could potentially be an interesting avenue for future research, we now think that it is premature to present a single model for how L,D-transpeptidases impact alkDADA labeling. At the same time, we do think that this observation is important in the larger context of metabolic labeling interpretation.

To resolve this conundrum, we have pared down the data to show only that alkDADA labeling decreases in *ldt* mutants (now Figure 4---figure supplement 2) but not in the presence of the L,Dtranspeptidase-targeting antibiotic imipenem (Figure 3B,E). We offer several models in the discussion that could explain this finding. Importantly, we also show that the global reduction in signal stems primarily from decreased signal at the poles but leaves sidewall labeling intact (now Figure 4---figure supplement 2B).

> 5\) Antibiotic titrations for labeling experiments would strengthen some observations. Is it possible that in the imipenem treated cells, destabilization of PG, and cell death is affecting probe uptake? Please address the issue of whether probe uptake is affected by cell death.

We have done additional titrations for ampicillin, imipenem and D-cycloserine and alkDA labeling (Figure 3C); titrations for imipenem and HADA, RADA and alkDADA labeling were formerly in Figure 2D, now Figure 3E.

We do not detect cell death in the time frame of the experiment (Figure 3---figure supplement 2). It is more difficult to rule out effects on cell growth or general defects in peptidoglycan metabolism. We have addressed this in Figure 3 by (1) examining probe incorporation in the presence of multiple peptidoglycan-acting antibiotics at different doses and (2) comparing our probes of interest to OalkTMM, which has an independent mechanism of incorporation (Foley et al., 2016).

Two pieces of evidence support a specific effect of imipenem on the monopeptide D-amino acid probes. First, ampicillin and vancomycin do not impact incorporation (Figure 3B,C). This argues against the idea that general peptidoglycan destabilization is responsible for the phenotype. Second, imipenem does not have much effect on alkDADA or OalkTMM incorporation in the time frame of this experiment (Figure 3B,E). We think that it is unlikely that growth inhibition alone would account for the specific effect of imipenem on monopeptide probe incorporation.

> 6\) Importantly, all reviewers have raised concerns with the way you have compiled and presented your manuscript. Two main issues that emerged are (I) this seems like an amalgamation of two stories (side wall labeling) and (FDAA probe uptake and related findings) and (II) the manuscript is hard to follow. Please give these comments careful attention when revising your manuscript. It would seem that the major focus of the manuscript is how FDAAs are taken up in mycobacteria. Perhaps you can start your manuscript with this aspect, develop it carefully using appropriate figures and models. Thereafter, you can discuss how the enhanced understanding of FDAAs developed in the manuscript assists with dissecting sidewall labeling. Revise your introduction and discussion (which is currently unnecessarily long) sections appropriately. Perhaps the title needs some reconsideration, to capture the revised focus of the manuscript. Due to the interdisciplinary nature of the work, additional schematics and summary figures would be helpful (in the manner done for Figure 2A). An information box re the chemistry would also help readability and would provide a format to highlight what is learned about these labels. There are some sections that could be moved to supplementary information to help streamline the results (such as Bocillin labeling, vanc staining, and some detail about polar elongation.

We have revised all sections of the manuscript, as suggested, and included four new schematics (Figures 1, Figure 6A). We appreciate the thoughtful suggestions from the editors and reviewers --- the work is now more focused and easier to understand.

[^1]: These authors contributed equally to this work.
